Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
:THRD
RESEARCH TOOLSreports
Holding THRD?
Track your performance easily
THRD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.60 - $16.94
Previous CloseN/A
Volume85.60K
Average Volume (3M)231.45K
Market Cap
$255.93M
Enterprise Value$267.16M
Total Cash (Recent Filing)$8.28M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Mar 26, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding45,058,414
10 Day Avg. Volume306,173
30 Day Avg. Volume231,448
Standard Deviation0.23
R-Squared0.23
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.06
Forecast
1Y Price Target
$16.67Price Target Upside187.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Third Harmonic Bio, Inc. News
PremiumCompany Announcements
Third Harmonic Bio Reports Q3 2024 Financial Results
PremiumCompany Announcements
Third Harmonic Bio Announces Executive Changes and Voting ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsThe progression of a Phase I study for the next-gen oral KIT inhibitor THB335 is on track, indicating a potential for future success.
Financial StabilityCash is sufficient to support operations through 2026, with the company ending the quarter with $296M in cash/equivalents, an increase from $255M at the end of the previous quarter.
Treatment AdvancementsCompetitive datasets have shown efficacy in chronic urticaria, and an oral option like THB335 could be well-received by patients and physicians.
Bears Say
Clinical TrialsTHB001 was discontinued because 2 patients in the Phase 1b CIndU study experienced transaminitis at a 200mg BID dose.
Drug ComparisonBLU-808 achieved tryptase reduction at much lower dose levels and with once daily dosing compared to THB001's twice daily dosing.
Drug EfficacyPK data supports QD dosing for BLU-808 and appears more potent than THRD's THB001.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Third Harmonic Bio, Inc. lowest stock price was $5.60 and its highest was $16.94 in the past 12 months.
What is Third Harmonic Bio, Inc.’s market cap?
Third Harmonic Bio, Inc.’s market cap is $255.93M.
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
Third Harmonic Bio, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 64 days.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Third Harmonic Bio, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.031.
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. does not currently pay dividends.
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Third Harmonic Bio, Inc. has 45,058,414 shares outstanding.
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Third Harmonic Bio, Inc. reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went up 4.974%.
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Currently, no hedge funds are holding shares in THRD
---
Third Harmonic Bio, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (187.91% Upside)
$16.67 (187.91% Upside)
Blogger Sentiment
Bullish
THRD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 628.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ―
Last 30 Days ―
Last 30 Days ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.29%
12-Months-Change
Fundamentals
Return on Equity
-13.81%
Trailing 12-Months
Asset Growth
7.88%
Trailing 12-Months
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company's lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
---
THRD Stock 12 Month Forecast
Average Price Target
$16.67
▲(187.91% Upside)
Technical Analysis
Adicet Bio
―
Iovance Biotherapeutics
―
Arcutis Biotherapeutics
―
Blueprint Medicines
―
Fate Therapeutics
―
Kura Oncology
―
Best Analysts Covering THRD
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
+10.75%
reiterated a buy rating 6 months ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +10.75% per trade.
---